KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Amneal Pharmaceuticals (AMRX) has 3 years of Long-Term Deferred Tax data on record, last reported at $391.9 million in Q2 2019.

  • For Q2 2019, Long-Term Deferred Tax rose 4.86% year-over-year to $391.9 million; the TTM value through Jun 2019 reached $391.9 million, up 4.86%, while the annual FY2018 figure was $373.2 million, 41454.45% up from the prior year.
  • Long-Term Deferred Tax reached $391.9 million in Q2 2019 per AMRX's latest filing, up from $382.9 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $391.9 million in Q2 2019 and bottomed at $898000.0 in Q4 2017.
  • Average Long-Term Deferred Tax over 3 years is $314.8 million, with a median of $373.4 million recorded in 2018.
  • Peak YoY movement for Long-Term Deferred Tax: soared 41454.45% in 2018, then increased 4.86% in 2019.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $898000.0 in 2017, then skyrocketed by 41454.45% to $373.2 million in 2018, then grew by 5.02% to $391.9 million in 2019.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $391.9 million in Q2 2019, $382.9 million in Q1 2019, and $373.2 million in Q4 2018.